NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ONESOURCE · data 2026-10-31
OneSource Specialty Pharma Limited
In plain words
Price: 18.8% below its 52-week high of ₹1,925.
Delivery: 48.2% of traded shares were kept for delivery over the last 10 sessions, against 51.5% over the last 60.
Latest results: a net profit of ₹5 cr for the quarter ended Mar 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,684 cr |
| Net profit (last 12 months) | ₹-2 cr |
| Sales growth, 3 years (yearly) | 232.4% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 30.5% (+0.7 pts in a year), pledged 38.8%, institutions 43.7%.
ROE -1.3%, ROCE -0.1%, operating margin 6.4%: how much profit it earns on the money it uses.
Debt/equity 0.26, Profit growth — and sales growth 232.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-1.3%).
- Promoters have pledged 38.8% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q4 FY26)
ONESOURCE Q4 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹428.22 crore.
Net profit was ₹4.6 crore.
Operating margin was 21.5%.
EPS was ₹0.4.
ONESOURCE के Q4 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹428.22 करोड़।
शुद्ध मुनाफ़ा: ₹4.6 करोड़।
ऑपरेटिंग मार्जिन: 21.5%।
EPS: ₹0.4।
ONESOURCEના Q4 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹428.22 કરોડ.
ચોખ્ખો નફો: ₹4.6 કરોડ.
ઓપરેટિંગ માર્જિન: 21.5%.
EPS: ₹0.4.
Written from the filed numbers. Not a recommendation.
Smart-money activity
25/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 9/30: Delivery 30.1% over the last 20 sessions vs 49.0% in the 40 before (0.61x); shares delivered per day 1.86x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 12 schemes hold it, about ₹286 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 45/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 13 May 26Results Q4 FY26 results: net profit ₹4.6 cr -0.6% next session
- 29 Jan 25Results Q3 FY25 results: net profit −₹67 cr +5.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Mar 2026 | ₹428 cr | ₹5 cr | — | 21.5% | 0.4 |
| Dec 2024 | ₹393 cr | ₹-67 cr | — | 36.5% | -6.31 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Sept 2025 | Jun 2025 |
|---|---|---|---|---|
| Promoters | 30.47% | 30.48% | 29.77% | 29.79% |
| Foreign institutions (FII) | 19.46% | 19.19% | 19.39% | 18.69% |
| Domestic institutions (DII) | 24.21% | 23.38% | 18.49% | 18.10% |
| Mutual funds | 13.76% | 12.98% | 8.99% | 9.06% |
| Retail investors | 9.95% | 9.31% | 9.24% | 9.35% |
| Number of shareholders | 79,770 | 77,899 | 87,416 | 87,760 |
Common questions
What was OneSource Specialty Pharma Limited's latest quarterly profit?
OneSource Specialty Pharma Limited reported a net profit of ₹5 cr for the quarter ended Mar 2026, on revenue of ₹428 cr.
How much do promoters hold in OneSource Specialty Pharma Limited?
Promoters held 30.47% of OneSource Specialty Pharma Limited at the end of Sept 2026, with 38.79% of promoter shares pledged.
Is OneSource Specialty Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.26.
What is the 52-week high and low of OneSource Specialty Pharma Limited?
The 52-week high is ₹1,925 and the 52-week low is ₹1,057.
Mutual funds holding OneSource Specialty Pharma Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 12 schemes holding about ₹286 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 3.01% | ₹105 cr |
| ADITYA BIRLA SUN LIFE VALUE FUND | Aditya Birla Sun Life Mutual Fund | 1.01% | ₹67 cr |
| Mirae Asset Aggressive Hybrid Fund | Mirae Asset Mutual Fund | 0.57% | ₹53 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.54% | ₹19 cr |
| Mirae Asset Multi Asset Allocation Fund | Mirae Asset Mutual Fund | 0.51% | ₹18 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.54% | ₹10 cr |
| ADITYA BIRLA SUN LIFE SPECIAL OPPORTUNITIES FUND | Aditya Birla Sun Life Mutual Fund | 0.64% | ₹9 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.41% | ₹5 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.54% | ₹0 cr |
| Mirae Asset BSE Select IPO ETF | Mirae Asset Mutual Fund | 0.87% | ₹0 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.89% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.54% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| OneSource Specialty Pharma Limited | ₹1,563 | ₹17,926 cr | — | 3 | -1.3% | -0.1% | 0.26 | -15.1% |
| Shilpa Medicare Limited | ₹955.6 | ₹18,671 cr | 62.9 | — | 9.8% | 9% | 0.25 | +166.2% |
| Caplin Point Laboratories Limited | ₹2,325.6 | ₹17,672 cr | 26.7 | — | 19.9% | 20.9% | 0 | +15.2% |
| Alivus Life Sciences Ltd | ₹1,415.3 | ₹17,284 cr | 26 | 4.8 | 18.4% | 22.4% | 0.02 | +55.2% |
| Cohance Lifesciences Ltd | ₹444.3 | ₹17,005 cr | 161 | 4.4 | 6.4% | 4.6% | 0.1 | -44.0% |
| PFIZER LIMITED | ₹3,687.8 | ₹16,867 cr | 23 | — | 17.2% | 20% | 0.02 | -30.0% |
Compare ONESOURCE with SHILPAMED in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ONESOURCE in NSE Scanner →